Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 18, 2025Frontiers in ImmunologyOpen Access

Blinatumomab demonstrates MRD eradication in MRD-positive/chemotherapy-delayed pediatric B-ALL and high response in relapsed/refractory cases: a multicenter cohort study

View Full Paper
Ask AI
Bookmark
Share

Authors

NZNa ZhangWHWenting HuYDYunpeng Dai

Discussion

Loading...

Member takes

Overview

Multicenter cohort study shows blinatumomab induces MRD eradication and high responses in relapsed/refractory cases.

Key Points

  • Blinatumomab achieved an overall MRD-negative rate of 97.8% among CR-MRD negative pediatric B-ALL patients.
  • The treatment saw a complete remission rate of 81.8% in relapsed/refractory cases, indicating high effectiveness.
  • Univariate analysis identified poor cytogenetics and BCR-ABL1 positivity as significant predictors of treatment resistance.
  • 1-year event-free survival was 97.8% for CR-MRD neg and 73.3% for relapsed/refractory patients, demonstrating long-term potential.

Cite This Study

Zhang et al. (2025) studied this question.

synapsesocial.com/papers/68d435cf713b0b5dfea74eb3https://doi.org/10.3389/fimmu.2025.1607138
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Blinatumomab efficacy differs between newly diagnosed and relapsed/refractory B-ALL: Impact on MRD clearance and survival2025
  2. 2Updated results of A phase II study of blinatumomab in adults with measurable residual disease of 10-4 or higher2025
  3. 3Blinatumomab vs. chemotherapy in pediatrics B-cell ALL: A meta-analysis of randomized controlled trials2025
  4. 4T-cell engaging bispecific antibody shows potent MRD negativity with variable remission and survival outcomes: A bayesian meta-analysis of randomized controlled trials2025
  5. 5Leukemia Burden Impacts the Efficacy and Toxicity of Blinatumomab in Pediatric B‐Cell Acute Lymphoblastic Leukemia2025